Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers

Journal of Thoracic Oncology

Volumn 1, Issue 9, 2006, Pages 932-942

  Lam, David C L ^a   Girard, Luc ^b   Suen, Wai Sing ^c   Chung, Lap Ping ^a   Tin, Vicky P C ^a   Lam, Wah Kit ^a   Minna, John D ^b   Wong, Maria P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Cell line; Lung adenocarcinoma; Non smokers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CARCINOGENICITY; CELL CYCLE; CELL LINE; CELL PROLIFERATION; EXON; FEMALE; GENDER; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INOCULATION; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; METASTASIS; MORPHOLOGY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; PRIORITY JOURNAL; SMOKING; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CHINA; COMPARATIVE STUDY; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CHINA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 34247850957     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200611000-00003     Document Type: Article

References (48)

1. Hospital Authority (Hong Kong China). Hong Kong Cancer Stat 2003. Hong Kong: Hong Kong Cancer Registry Hospital Authority, 2003:v.
2. Parkin DM. International Agency for Research on C, International Association of Cancer R. Cancer Incidence in Five Continents, Volume VIII. Lyon, France: International Agency for Research on Cancer, 2002.
3. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992;3:61-64.
4. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88:183-192.
5. Sugaya M, Takenoyama M, Osaki T, et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002;122:282-288.
6. Oie HK, Russell EK, Carney DN, et al. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl 1996;24:24-31.
7. Tai AL, Fang Y, Sham JS, et al. Establishment and characterization of a human non-small cell lung cancer cell line. Oncol Rep 2005;13:1029-1032.
8. Chikamori M, Takigawa N, Kiura K, et al. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res 2004;24:3911-3916.
9. Koizumi F, Shimoyama T, Taguchi F, et al. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 2005;116:36-44.
10. Sharifzadeh S, Owji SM, Pezeshki AM, et al. Establishment and characterization of a human large cell lung cancer cell line with neuroendocrine differentiation. Pathol Oncol Res 2004;10:225-230.
11. Affymetrix. Microarray Suite User Guide 5.0.
12. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004;64:9027-9034.
13. Simon R, Lam AP. BRB ArrayTools version 3.3.0, 2005.
14. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12:1647-1653.
15. Hsieh SY, Hsieh PS, Chiu CT, et al. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23:9183-9189.
16. Kobayashi K, Ouchida M, Tsuji T, et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 2002;282:151-158.
17. Hosomichi J, Yasui N, Koide T, et al. Involvement of the collagen I-binding motif in the anti-angiogenic activity of pigment epitheliumderived factor. Biochem Biophys Res Commun 2005;335:756-761.
18. Mahtabifard A, Merritt RE, Yamada RE, et al. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 2003;126:28-38.
19. Zhang L, Chen J, Ke Y, et al. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int J Mol Med 2006;17:937-944.
20. Marchong MN, Chen D, Corson TW, et al. Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma. Mol Cancer Res 2004;2:495-503.
21. Kashima T, Nakamura K, Kawaguchi J, et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 2003;104:147-154.
22. Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res 2005;7:R669-680.
23. Slavin DA, Koritschoner NP, Prieto CC, et al. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun protooncoprotein function. Oncogene 2004;23:8196-8205.
24. Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-2566.
25. Reeves HL, Narla G, Ogunbiyi O, et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004;126:1090-1103.
26. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005;32:315-328.
27. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-262.
28. Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clin Adv Hematol Oncol 2003;1:466-472.
29. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
30. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-1646.
31. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-5018.
32. Hirata A, Hosoi F, Miyagawa M, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005;65:4253-4260.
33. Cappuzzo F, Toschi L, Domenichini I, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005;93:1334-1340.
34. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933-8938.
35. Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001;276:13057-13064.
36. Awaya H, Takeshima Y, Yamasaki M, et al. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004;121:644-653.
37. Baldus SE, Monig SP, Huxel S, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004;10:2790-2796.
38. Canbay E. Erb-B2 homodimerization inhibits MUC1 transcription in cultured human mammary epithelial cells. Cell Biol Int 2003;27:477-481.
39. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14567-14571.
40. O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005;23:9022-9028.
41. Moores SL, Selfors LM, Fredericks J, et al. Vav family proteins couple to diverse cell surface receptors. Mol Cell Biol 2000;20:6364-6373.
42. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005;7:39-49.
43. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005;7:167-178.
44. Jarmalaite S, Kannio A, Anttila S, et al. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003;106:913-918.
45. Shimamoto T, Ohyashiki JH, Hirano T, et al. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. Oncol Rep 2004;12:389-395.
46. Anand N, Murthy S, Amann G, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-305.
47. Lee YG, Macoska JA, Korenchuk S, et al. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 2002;4:291-294.
48. Wistuba II, Behrens C, Milchgrub S, et al. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res 1998;4:2931-2938.